1Loyd-Jones DM, Evans JC, Larson MG, et al. Cross-classification of JNC Ⅳ blood pressure stages and risk groups in the Framingham Heart Study[J]. Arch Intern Med, 1999, 159(18) :2206-2212.
2Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial[ J ]. Lancet, 2002, 360 (9326) : 7-22.
3Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial[ J ]. Lancet, 2004, 363 (9426) :2022-2031.
4Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome[J]. Am J Cardiol, 2003, 91(12) : 1421-1426.
5Kanbay M, Yildirir A, Bozbas H, et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemie patients [ J ]. Ren Fail, 2005,27 ( 3 ) :297-303.
6Borghi C, Gaddi A, Ambrosioni E. Improved blood pressure control in hypertensive patients treated with statins[J]. J Am Coll Cardiol, 2002, 37 ( Suppl A) :233-234.
7Messerli FH, Bakris GL, Ferrera D, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial[ J]. J Clin Hypertens ( Greenwich) ,2006, 8(8) :571-581.
8Sever P, Dahlof B, Pouher N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the anglo-scandinavian cardiac outcomes triM[J]. Eur Heart J, 2006, 27 (24) :2982-2988.
9The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcome in moderate hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: the antihypertensire and lipid-lowering treatment to prevent heart attack trial (ALLHALLT) [J]. JAMA, 2002, 288(23): 2998 -3007.
10Chapman RH, Petrilla AA, Benner JS, et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults : a retrospective, cohort study [ J ]. Drugs aging, 2008,25 ( 10 ) : 885 -892.
3Makita S, Abiko A, Naganuma Y, et al. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance [ J ]. Metabolism, 2008,57 (10) : 1473-1478.
4Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pres- sure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome [ J ]. Hypertens Res, 2008,31 ( 5 ) :921-929.
5Yamana A, Arita M, Furuta M, et al. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control [ J ]. Diabetes Res Clin Pract,2008, 82( 1 ) :127-131.
6Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-actived receptorgamma[ J]. Diabetes, 2004,52(4) :910-917.
7魏克立.口腔粘膜病学[M].5版.北京:科学出版社,2006.49-54.
8史宗道,王晓娟.口腔临床药物学[M].2版.北京:人民卫生出版社,2008:96-97.
9Safayhi H, Sabieraj J, Sailer ER, et al. Chamazalene : an antioxidant-- type inhibitor of Leukotriene B4 formation [ J ]. Planta Med, 1994, 60 (J) :410-413.
10Makita S,Abiko A,Naganuma Y,et al.Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance[J].metabolism,2008,57(10):1473-1478.
